Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 3/20 | 0.36 |
| ▸ | PDE2A | O00408 | 12/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.36 |
| ▸ | DHODH | Q02127 | 3/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17678700 | 0.91 | PDE2A (0.38) | OPRK1PDE2APDE10ACYP11B2AKT1 | |
| SCHEMBL19699778 | 0.88 | OPRK1 (0.37) | OPRK1PDE10ADHODH | |
| SCHEMBL17675584 | 0.86 | OPRK1 (0.51) | OPRK1 | |
| SCHEMBL19706977 | 0.84 | OPRK1 (0.44) | OPRK1DHODHCYP11B2 | |
| SCHEMBL17674350 | 0.81 | OGA (0.38) | OPRK1DHODH | |
| SCHEMBL19454504 | 0.80 | LRRK2 (0.36) | OPRK1AKT1MAP3K5 | |
| SCHEMBL24187946 | 0.79 | BACE1 (0.37) | PDE2APDE10AAKT1MAP3K5 | |
| SCHEMBL17845850 | 0.79 | VNN1 (0.40) | OPRK1 | |
| SCHEMBL19454416 | 0.77 | VNN1 (0.33) | OPRK1 | |
| SCHEMBL20599108 | 0.76 | GAK (0.42) | DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11534439-B2 | Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2022-12-27 | — | — | US | disclosed |
| US-20220016112-A1 | DIHYDROQUINOXALINE AND DIHYDROPYRIDOPYRAZINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2022-01-20 | — | — | US | disclosed |
| WO-2022010882-A1 | DIHYDROQUINOXALINE AND DIHYDROPYRIDOPYRAZINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC, (US) | 2022-01-13 | — | — | WO | disclosed |
| US-10626126-B2 | Compounds | PULMOCIDE LIMITED (GB) | 2020-04-21 | — | — | US | disclosed |
| US-10626126-B2 | Compounds | PULMOCIDE LIMITED (GB) | 2020-04-21 | — | — | US | disclosed |
| US-20190092791-A1 | COMPOUNDS | PULMOCIDE LIMITED (GB) | 2019-03-28 | — | — | US | disclosed |
| US-20190092791-A1 | COMPOUNDS | PULMOCIDE LIMITED (GB) | 2019-03-28 | — | — | US | disclosed |
| US-10189863-B2 | 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives | PULMOCIDE LIMITED (GB) | 2019-01-29 | — | — | US | disclosed |
| US-10189863-B2 | 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives | PULMOCIDE LIMITED (GB) | 2019-01-29 | — | — | US | disclosed |
| US-10160772-B2 | 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives | PULMOCIDE LIMITED (GB) | 2018-12-25 | — | — | US | disclosed |
| US-20170355717-A1 | NOVEL 5,6-DIHYDRO-4H-BENZO[B]THIENO-[2,3-D]AZEPINE DERIVATIVES | PULMOCIDE LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
| US-20170355717-A1 | NOVEL 5,6-DIHYDRO-4H-BENZO[B]THIENO-[2,3-D]AZEPINE DERIVATIVES | PULMOCIDE LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
| EP-3233867-A1 | 4,5-DIHYDRO-6H-THIENO[3,2-D]BENZAZEPINE DERIVATIVES AND THEIR USE TO TREAT RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTIONS | Pulmocide Limited (GB) | 2017-10-25 | — | — | EP | disclosed |
| WO-2017175000-A1 | COMPOUNDS | PULMOCIDE LIMITED (GB) | 2017-10-12 | — | — | WO | disclosed |
| WO-2017175000-A1 | COMPOUNDS | PULMOCIDE LIMITED (GB) | 2017-10-12 | — | — | WO | disclosed |
| EP-3204388-A1 | NOVEL 5,6-DIHYDRO-4H-BENZO[B]THIENO-[2,3-D]AZEPINE DERIVATIVES | Pulmocide Limited (GB) | 2017-08-16 | — | — | EP | disclosed |
| WO-2016097761-A1 | 4,5-DIHYDRO-6H-THIENO[3,2-D]BENZAZEPINE DERIVATIVES AND THEIR USE TO TREAT RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTIONS | PULMOCIDE LIMITED (GB) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016097761-A1 | 4,5-DIHYDRO-6H-THIENO[3,2-D]BENZAZEPINE DERIVATIVES AND THEIR USE TO TREAT RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTIONS | PULMOCIDE LIMITED (GB) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016055792-A1 | NOVEL 5,6-DIHYDRO-4H-BENZO[B]THIENO-[2,3-D]AZEPINE DERIVATIVES | PULMOCIDE LIMITED (GB) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016055792-A1 | NOVEL 5,6-DIHYDRO-4H-BENZO[B]THIENO-[2,3-D]AZEPINE DERIVATIVES | PULMOCIDE LIMITED (GB) | 2016-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11534439-B2 | Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors | SIRT5, QDPR, NOX5 | OPRK1 3581/4885PDE2A 1042/4885PDE10A 3095/4885 |
| US-10626126-B2 | Compounds | QDPR, TXNRD2, TXNRD3 | OPRK1 4316/4885PDE2A 946/4885PDE10A 3149/4885 |
| US-10189863-B2 | 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives | AZI2, HRH4, ZC3HAV1 | OPRK1 2683/4885PDE2A 1795/4885PDE10A 3427/4885 |
| US-20190092791-A1 | COMPOUNDS | QDPR, TXNRD2, TXNRD3 | OPRK1 4316/4885PDE2A 946/4885PDE10A 3149/4885 |
| US-10160772-B2 | 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives | ZC3HAV1, DDX5, DPP4 | OPRK1 3339/4885PDE2A 1610/4885PDE10A 2807/4885 |
| US-20220016112-A1 | DIHYDROQUINOXALINE AND DIHYDROPYRIDOPYRAZINE DERIVATIVES AS RSV INHIBITORS | SIRT5, QDPR, NOX5 | OPRK1 3581/4885PDE2A 1042/4885PDE10A 3095/4885 |
| US-20170355717-A1 | NOVEL 5,6-DIHYDRO-4H-BENZO[B]THIENO-[2,3-D]AZEPINE DERIVATIVES | ZC3HAV1, DHX15, AZI2 | OPRK1 2897/4885PDE2A 1661/4885PDE10A 2995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.